IBIO insider trading
NasdaqCM HealthcareiBio, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company website: ibioinc.com
IBIO insider activity at a glance
FilingIQ has scored 101 insider transactions for IBIO since Sep 5, 2014. The most recent filing in our index is dated Mar 26, 2026.
Across the full history, 16 open-market purchases
and 25 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IBIO insider trades is 58.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IBIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading IBIO
Frequently asked
- How many insider trades does FilingIQ track for IBIO?
- FilingIQ tracks 101 Form 4 insider transactions for IBIO (iBio, Inc.), covering filings from Sep 5, 2014 onwards. 4 of those were filed in the last 90 days.
- Are IBIO insiders net buyers or net sellers?
- Across the full Form 4 history for IBIO, 16 transactions (16%) were open-market purchases and 25 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IBIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IBIO in?
- iBio, Inc. (IBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $92.89M.
Methodology & sources
Every IBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.